deltatrials
Terminated PHASE2 INTERVENTIONAL 1-arm NCT03840967

A Study Evaluating Safety and Efficacy of Niraparib in Patients With Previously Treated Metastatic Esophageal/Gastroesophageal Junction/Proximal Gastric Adenocarcinoma

A Phase II Study Evaluating Safety and Efficacy of Niraparib in Patients With Previously Treated Homologous Recombination (HR) Defective or Loss of Heterozygosity (LOH) High Metastatic Esophageal/Gastroesophageal Junction/Proximal Gastric Adenocarcinoma

Sponsor: GlaxoSmithKline

Conditions Adenocarcinoma Esophageal Cancer Gastric Cancer
Interventions Niraparib
Updated 20 times since 2019 Last updated: May 6, 2024 Started: Jul 9, 2019 Primary completion: Nov 17, 2022 Completion: Feb 22, 2023
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Terminated

Due to slow accruals

Other terminated trials from GlaxoSmithKline

See all terminations from GlaxoSmithKline

Other Adenocarcinoma trials with similar outcome

Browse all Adenocarcinoma trials

A PHASE2 clinical study on Adenocarcinoma and Esophageal Cancer, this trial is terminated or withdrawn. The trial is conducted by GlaxoSmithKline and has accumulated 20 data snapshots since 2019. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.

Status Flow

~Mar 2019 – ~May 2019 · 2 months · monthly snapshot~May 2019 – ~Aug 2019 · 3 months · monthly snapshot~Aug 2019 – ~Sep 2019 · 31 days · monthly snapshot~Sep 2019 – ~Nov 2019 · 2 months · monthly snapshot~Nov 2019 – ~Jan 2020 · 2 months · monthly snapshot~Jan 2020 – ~May 2020 · 4 months · monthly snapshot~May 2020 – ~Aug 2020 · 3 months · monthly snapshot~Aug 2020 – ~Jan 2021 · 5 months · monthly snapshot~Jan 2021 – ~Mar 2021 · 59 days · monthly snapshot~Mar 2021 – ~May 2021 · 2 months · monthly snapshot~May 2021 – ~Nov 2021 · 6 months · monthly snapshot~Nov 2021 – ~Mar 2022 · 4 months · monthly snapshot~Mar 2022 – ~Jun 2022 · 3 months · monthly snapshot~Jun 2022 – ~Feb 2023 · 8 months · monthly snapshot~Feb 2023 – ~Apr 2023 · 59 days · monthly snapshot~Apr 2023 – ~Jun 2023 · 2 months · monthly snapshot~Jun 2023 – ~Mar 2024 · 9 months · monthly snapshot~Mar 2024 – ~Jul 2024 · 4 months · monthly snapshot~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshot~Sep 2024 – present · 24 months · monthly snapshot

Change History

20 versions recorded

  1. Sep 2024 — Present [monthly]

    Terminated PHASE2

  2. Jul 2024 — Sep 2024 [monthly]

    Terminated PHASE2

    Status: Active Not Recruiting → Terminated

  3. Mar 2024 — Jul 2024 [monthly]

    Active Not Recruiting PHASE2

  4. Jun 2023 — Mar 2024 [monthly]

    Active Not Recruiting PHASE2

  5. Apr 2023 — Jun 2023 [monthly]

    Active Not Recruiting PHASE2

    Status: Recruiting → Active Not Recruiting

▶ Show 15 earlier versions

  1. Feb 2023 — Apr 2023 [monthly]

    Recruiting PHASE2

  2. Jun 2022 — Feb 2023 [monthly]

    Recruiting PHASE2

  3. Mar 2022 — Jun 2022 [monthly]

    Recruiting PHASE2

  4. Nov 2021 — Mar 2022 [monthly]

    Recruiting PHASE2

  5. May 2021 — Nov 2021 [monthly]

    Recruiting PHASE2

  6. Mar 2021 — May 2021 [monthly]

    Recruiting PHASE2

  7. Jan 2021 — Mar 2021 [monthly]

    Recruiting PHASE2

  8. Aug 2020 — Jan 2021 [monthly]

    Recruiting PHASE2

  9. May 2020 — Aug 2020 [monthly]

    Recruiting PHASE2

  10. Jan 2020 — May 2020 [monthly]

    Recruiting PHASE2

  11. Nov 2019 — Jan 2020 [monthly]

    Recruiting PHASE2

  12. Sep 2019 — Nov 2019 [monthly]

    Recruiting PHASE2

    Status: Not Yet Recruiting → Recruiting

  13. Aug 2019 — Sep 2019 [monthly]

    Not Yet Recruiting PHASE2

  14. May 2019 — Aug 2019 [monthly]

    Not Yet Recruiting PHASE2

  15. Mar 2019 — May 2019 [monthly]

    Not Yet Recruiting PHASE2

    First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • GlaxoSmithKline
  • Indiana University School of Medicine
  • Shadia Jalal, MD
Data source: Hoosier Cancer Research Network

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations